AstraZeneca PLC (NYSE:AZN) is among the Best Biotech Stocks. On May 1, CNBC reported that an FDA advisory panel voted 6-3 against allowing AstraZeneca PLC (NYSE:AZN)’s oral breast cancer drug ...
AstraZeneca's Oncology and Rare Disease segments delivered 16% and 15% growth, powered by IMFINZI and ULTOMIRIS, respectively ...
AstraZeneca reported Q1 2026 Total Revenue of $15.3 billion, up 8% at constant exchange rates, driven by double-digit growth in oncology and rare disease, with core operating profit up 12% and core ...
AstraZeneca PLC (NASDAQ:AZN) has a strong lineup of drugs in development, which should help it navigate upcoming patent expirations. By the end of the first quarter, it had secured around 13 drug ...
Is AZN a good stock to buy? We came across a bullish thesis on AstraZeneca PLC on South Sea Investing’s Substack. In this article, we will summarize the bulls’ thesis on AZN. AstraZeneca PLC’s share ...
Investors in AstraZeneca plc (Symbol: AZN) saw new options become available this week, for the February 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AZN ...
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...
AstraZeneca reported positive interim Phase III data from the VOLGA trial showing that perioperative Imfinzi combined with neoadjuvant enfortumab vedotin significantly improved event-free and overall ...
Zacks Investment Research on MSN
AZN, Daiichi's Enhertu gets positive CHMP opinion for solid tumors
AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the European Medicines Agency's (EMA) Committee for ...
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results